Correlation Between Pharvaris and Qualigen Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Pharvaris and Qualigen Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Pharvaris and Qualigen Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Pharvaris BV and Qualigen Therapeutics, you can compare the effects of market volatilities on Pharvaris and Qualigen Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Pharvaris with a short position of Qualigen Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Pharvaris and Qualigen Therapeutics.

Diversification Opportunities for Pharvaris and Qualigen Therapeutics

-0.61
  Correlation Coefficient

Excellent diversification

The 3 months correlation between Pharvaris and Qualigen is -0.61. Overlapping area represents the amount of risk that can be diversified away by holding Pharvaris BV and Qualigen Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Qualigen Therapeutics and Pharvaris is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Pharvaris BV are associated (or correlated) with Qualigen Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Qualigen Therapeutics has no effect on the direction of Pharvaris i.e., Pharvaris and Qualigen Therapeutics go up and down completely randomly.

Pair Corralation between Pharvaris and Qualigen Therapeutics

Given the investment horizon of 90 days Pharvaris BV is expected to generate 0.79 times more return on investment than Qualigen Therapeutics. However, Pharvaris BV is 1.26 times less risky than Qualigen Therapeutics. It trades about -0.05 of its potential returns per unit of risk. Qualigen Therapeutics is currently generating about -0.13 per unit of risk. If you would invest  2,335  in Pharvaris BV on August 29, 2024 and sell it today you would lose (194.00) from holding Pharvaris BV or give up 8.31% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthWeak
Accuracy100.0%
ValuesDaily Returns

Pharvaris BV  vs.  Qualigen Therapeutics

 Performance 
       Timeline  
Pharvaris BV 

Risk-Adjusted Performance

12 of 100

 
Weak
 
Strong
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Pharvaris BV are ranked lower than 12 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively fragile basic indicators, Pharvaris unveiled solid returns over the last few months and may actually be approaching a breakup point.
Qualigen Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Qualigen Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's technical and fundamental indicators remain very healthy which may send shares a bit higher in December 2024. The recent disarray may also be a sign of long period up-swing for the firm investors.

Pharvaris and Qualigen Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Pharvaris and Qualigen Therapeutics

The main advantage of trading using opposite Pharvaris and Qualigen Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Pharvaris position performs unexpectedly, Qualigen Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Qualigen Therapeutics will offset losses from the drop in Qualigen Therapeutics' long position.
The idea behind Pharvaris BV and Qualigen Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.

Other Complementary Tools

Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume